Literature DB >> 15846059

Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.

Sumaira Amir1, Naira V Margaryan, Valerie Odero-Marah, Zhila Khalkhali-Ellis, Mary J C Hendrix.   

Abstract

Maspin, a unique serine proteinase inhibitor (serpin), plays a key role in mammary gland development and is silenced during breast cancer progression. Maspin has been shown to inhibit tumor cell motility and invasion in cell culture, as well as growth and metastasis in animal models. In this study, we investigated the effect of maspin on the regulation of hypoxia-induced expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), with respect to invasive potential in metastatic breast cells MDA-MB-231. We hypothesized that maspin can neutralize or mitigate hypoxia-induced expression of uPA/uPAR in metastatic breast cancer cells, resulting in suppression of their invasive potential. To test our hypothesis, we employed the highly invasive MDA-MB-231 breast cancer cells that are devoid of maspin, and transfected them with the maspin gene, and then determined the effect of hypoxia on uPA/uPAR expression. Normal mammary epithelial cells 1436N1 were used as a control. Our findings demonstrate that maspin downregulated the basal and hypoxia-induced uPA/uPAR expression and reduced the stimulatory effect of hypoxia on the in vitro invasive ability of MDA-MB-231-cells. In addition, maspin also inhibited the enzymatic activity of secreted and cell associated uPA in MDA-MB-231 cells. These results indicate that maspin inhibits hypoxia-induced invasion of metastatic breast cancer cells by blocking the uPA system, thus illuminating an important molecular pathway for therapeutic consideration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846059      PMCID: PMC3175738          DOI: 10.4161/cbt.4.4.1617

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  46 in total

1.  Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.

Authors:  H Biliran; S Sheng
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

2.  Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway.

Authors:  C H Graham; T E Fitzpatrick; K R McCrae
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

3.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.

Authors:  Y Go; S K Chintala; S Mohanam; Z Gokaslan; B Venkaiah; R Bjerkvig; K Oka; G L Nicolson; R Sawaya; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

Review 4.  The urokinase-type plasminogen activator system in cancer metastasis: a review.

Authors:  P A Andreasen; L Kjøller; L Christensen; M J Duffy
Journal:  Int J Cancer       Date:  1997-07-03       Impact factor: 7.396

5.  Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.

Authors:  A Mazumdar; L Adam; D Boyd; R Kumar
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

Review 6.  The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.

Authors:  Y Wang
Journal:  Med Res Rev       Date:  2001-03       Impact factor: 12.944

7.  Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.

Authors:  R Bos; H Zhong; C F Hanrahan; E C Mommers; G L Semenza; H M Pinedo; M D Abeloff; J W Simons; P J van Diest; E van der Wall
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

8.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study.

Authors:  B Movsas; J D Chapman; R E Greenberg; A L Hanlon; E M Horwitz; W H Pinover; C Stobbe; G E Hanks
Journal:  Cancer       Date:  2000-11-01       Impact factor: 6.860

Review 9.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.

Authors:  J M Brown
Journal:  Cancer Res       Date:  1999-12-01       Impact factor: 12.701

10.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

View more
  7 in total

1.  Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.

Authors:  Debra J Warejcka; Malathi Narayan; Sally S Twining
Journal:  Exp Eye Res       Date:  2011-07-27       Impact factor: 3.467

2.  Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT.

Authors:  S McKenzie; S Sakamoto; N Kyprianou
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

3.  p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.

Authors:  Peixin Dong; Mitsuhiro Tada; Jun-Ichi Hamada; Akihiro Nakamura; Tetsuya Moriuchi; Noriaki Sakuragi
Journal:  Clin Exp Metastasis       Date:  2007-07-18       Impact factor: 5.150

4.  NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo.

Authors:  Jiahua Jiang; Anita Thyagarajan-Sahu; Viktor Krchňák; Andrej Jedinak; George E Sandusky; Daniel Sliva
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

5.  Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells.

Authors:  Corey L Neal; Veronica Henderson; Bethany N Smith; Danielle McKeithen; Tisheeka Graham; Baohan T Vo; Valerie A Odero-Marah
Journal:  BMC Cancer       Date:  2012-08-02       Impact factor: 4.430

6.  Elevated maspin expression is associated with better overall survival in esophageal squamous cell carcinoma (ESCC).

Authors:  Yang Wang; Shijie Sheng; Jianzhi Zhang; Sijana Dzinic; Shaolei Li; Fang Fang; Nan Wu; Qingfeng Zheng; Yue Yang
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

7.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.